Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noae221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Domique Figarella-Branger und 12 weiteren Autor:innen. Beteiligte Einrichtung: APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Oligodendroglioma, Chromosomes, Human, Pair 19, Chromosomes, Human, Pair 1. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Institut National du Cancer.
Abstract (Originalsprache)
Background
In the POLA cohort, 3 pathological groups of CNS WHO grade 3 oligodendroglioma IDH-mutant and 1p/19q co-deleted have been described: group 1 (high mitotic count only), group 2 (microvascular proliferation MVP and no necrosis), and group 3 (MVP and necrosis).
Methods
494 patients from the POLA cohort, with a median follow-up of 96 months were included. To identify the impact of the pathological groups and contrast enhancement (CE) in group 1 on overall survival (OS) or progression-free survival (PFS), survival curves were obtained (Kaplan–Meier method) and compared (log-rank test). The prognostic value of clinical factors and CDKN2A homozygous deletion HD were also tested. Multivariate analysis was performed.
Results
Survival analysis demonstrated that the pathological groups were associated with both progression-free survival (PFS P = .01) and overall survival (OS P = .001). In group 1, patients with CE (1CE+) had a poorer prognosis compared to those without (OS P = .028, PFS P = .006). Further stratification into group 1CE−, group 1CE+, group 2, and group 3 provided clearer prognostic distinctions (OS P = .002, PFS P < .0001). Other prognostic factors included age (OS P < .0001, PFS P = .002), extent of surgical resection (OS P = .001, PFS P = .003), KPS (OS P < .0001, PFS P = 0.002), postoperative treatment (OS P = .007, PFS P < .0001), and CDKN2A HD (OS and PFS P < .0001). The pathological groups remained of prognostic significance for PFS in multivariate analysis.
Conclusions
Necrosis and CDKN2A HD are adverse prognostic factors of WHO grade 3 oligodendrogliomas, IDH-mutant, and 1p/19q co-deleted. Besides, in group 1 patients, lack of CE is a factor of better prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.
- Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, GlioME Team, Marseille, France.
- Aix-Marseille Univ, Réseau PrEclinique et TRAnslationnel de Recherche en Neuro-Oncologie, Plateforme PETRA"TECH", Marseille, France.
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France.
- AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuropathologie-Escourolle, Paris, France.
- INSERM U1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
ORCID-Profile: Domique Figarella-Branger, Carole Colin, Ahmed Idbaih, Emeline Tabouret, Mehdi Touat, Antoine Seyve
Förderung
- Institut National du Cancer
Zitieren
APA
Figarella-Branger, D., Colin, C., Mokhtari, K., Uro-Coste, E., Idbaih, A., Appay, R., Tabouret, E., Touat, M., Seyve, A., Carpentier, C., Dehais, C., Ducray, F., & POLA network (2025). Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae221
Vancouver
Figarella-Branger D, Colin C, Mokhtari K, Uro-Coste E, Idbaih A, Appay R, et al. Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae221
BibTeX
@article{FigarellaBranger2025,
author = {Figarella-Branger, Domique and Colin, Carole and Mokhtari, Karima and Uro-Coste, Emmanuelle and Idbaih, Ahmed and Appay, Romain and Tabouret, Emeline and Touat, Mehdi and Seyve, Antoine and Carpentier, Catherine and Dehais, Caroline and Ducray, François and POLA network, POLA network},
title = {Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noae221}
}
EUVIMED